Xtant Medical (NYSEAMERICAN:XTNT - Get Free Report) is expected to announce its earnings results after the market closes on Thursday, March 6th. Analysts expect Xtant Medical to post earnings of ($0.02) per share and revenue of $31.80 million for the quarter. Parties that wish to register for the company's conference call can do so using this link.
Shares of NYSEAMERICAN:XTNT remained flat at $0.45 during trading on Tuesday. The stock had a trading volume of 98,895 shares, compared to its average volume of 97,122. The stock has a market cap of $62.55 million, a PE ratio of -3.46 and a beta of 0.35. Xtant Medical has a 1-year low of $0.33 and a 1-year high of $1.24. The company has a quick ratio of 0.88, a current ratio of 2.12 and a debt-to-equity ratio of 0.42.
Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.
Before you consider Xtant Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xtant Medical wasn't on the list.
While Xtant Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.